Vericel Co. (NASDAQ:VCEL) Insider Jonathan Siegal Sells 1,092 Shares of Stock

Vericel Co. (NASDAQ:VCEL) insider Jonathan Siegal sold 1,092 shares of the stock in a transaction on Wednesday, February 5th. The shares were sold at an average price of $61.99, for a total transaction of $67,693.08. Following the completion of the transaction, the insider now owns 1,206 shares of the company’s stock, valued at approximately $74,759.94. This represents a 47.52 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink.

Jonathan Siegal also recently made the following trade(s):

• On Tuesday, January 28th, Jonathan Siegal sold 3,908 shares of Vericel stock. The shares were sold at an average price of $61.99, for a total value of $242,256.92.

Vericel Trading Down 2.3 %

Shares of NASDAQ VCEL opened at $58.35 on Friday. The company has a market cap of $2.88 billion, a PE ratio of 972.66 and a beta of 1.72. The company has a 50-day moving average of $57.84 and a two-hundred day moving average of $51.11. Vericel Co. has a 1-year low of $39.12 and a 1-year high of $63.00.

Vericel (NASDAQ:VCEL) last posted its quarterly earnings data on Thursday, November 7th. The biotechnology company reported ($0.02) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.05) by $0.03. The firm had revenue of $57.91 million for the quarter, compared to the consensus estimate of $55.32 million. Vericel had a return on equity of 1.48% and a net margin of 1.56%. As a group, equities research analysts forecast that Vericel Co. will post 0.14 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several research firms recently commented on VCEL. HC Wainwright restated a “buy” rating and set a $60.00 target price on shares of Vericel in a research report on Wednesday, January 15th. Truist Financial boosted their target price on shares of Vericel from $61.00 to $67.00 and gave the company a “buy” rating in a research note on Wednesday, December 18th. Canaccord Genuity Group increased their target price on shares of Vericel from $64.00 to $67.00 and gave the stock a “buy” rating in a research report on Monday, February 3rd. StockNews.com raised shares of Vericel from a “sell” rating to a “hold” rating in a research note on Tuesday, December 24th. Finally, BTIG Research lifted their target price on shares of Vericel from $56.00 to $66.00 and gave the company a “buy” rating in a research note on Tuesday, November 26th. One equities research analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $63.14.

Institutional Trading of Vericel

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in VCEL. International Assets Investment Management LLC boosted its stake in shares of Vericel by 4,126.7% in the 3rd quarter. International Assets Investment Management LLC now owns 634 shares of the biotechnology company’s stock valued at $27,000 after purchasing an additional 619 shares during the last quarter. Arcadia Investment Management Corp MI acquired a new position in Vericel in the fourth quarter valued at approximately $48,000. Farther Finance Advisors LLC boosted its stake in Vericel by 48.1% in the third quarter. Farther Finance Advisors LLC now owns 1,247 shares of the biotechnology company’s stock valued at $53,000 after acquiring an additional 405 shares during the last quarter. Smartleaf Asset Management LLC grew its holdings in Vericel by 511.1% during the 4th quarter. Smartleaf Asset Management LLC now owns 1,265 shares of the biotechnology company’s stock worth $70,000 after acquiring an additional 1,058 shares during the period. Finally, Mirae Asset Global Investments Co. Ltd. raised its position in shares of Vericel by 22.2% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,773 shares of the biotechnology company’s stock valued at $77,000 after acquiring an additional 322 shares during the last quarter.

About Vericel

Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns.